Artificial heart maker Carmat announces progress on its Aeson device (updated)

Carmat SA

23/10/2023 07:04

(Adds quote, details)
       PARIS, Oct 23 (Reuters) - Carmat  ALCAR.PA , the
artificial heart maker which this month got a 7 million euros
($7.40 million) lifeline to survive an imminent cash crunch, on
Monday announced solid progress for its Aeson artificial heart
device.
    Carmat said it had performed seven Aeson implants as part of
a clinical study in Paris and that it hoped to complete the
study in 2025, in line with the company's targets.
    “This ramp-up is the result of growing experience in patient
selection and attests to the steep learning curve of the
surgical procedure,” said Professor Christian Latremouille,
Director of Surgical Affairs at Carmat, in a press release.
    The clinical study, called EFICAS, is a prospective study
designed to include 52 patients eligible for transplants,
currently enrolled by a network of six French cardiology
centers, Carmat said.
    The primary objective of the study is 180-day
post-implantation survival without disabling stroke or
successful heart transplant within 180 days of implantation, the
company said.
     The study also aims to assess state reimbursement of the
device in France.

    ($1 = 0.9457 euros)

 (Reporting by Sudip Kar-Gupta and Michal Aleksandrowicz;
Editing by Jamie Freed and Janane Venkatraman)
 ((sudip.kargupta@thomsonreuters.com;))